Welcome to Paid Research Studies


Browse Locations ... United States» ... Pennsylvania» ... Bethlehem






  • Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Tofacitinib;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting - verified July 2014

  • Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathies
    Interventions:   Drug: Canagliflozin;   Drug: Placebo
    Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
    Recruiting - verified July 2014

  • Conditions:   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
    Interventions:   Drug: brentuximab vedotin;   Drug: crizotinib;   Drug: dexamethasone;   Drug: ifosfamide;   Drug: methotrexate;   Drug: cytarabine;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Anaemia
    Interventions:   Drug: GSK1278863;   Drug: rhEPO
    Sponsor:   GlaxoSmithKline
    Recruiting - verified July 2014

  • Condition:   Hypercholesterolemia
    Intervention:   Drug: Atorvastatin calcium 10 mg
    Sponsor:   Pfizer
    Recruiting - verified June 2014

  • Condition:   Melanoma
    Interventions:   Drug: LGX818;   Drug: LGX818+MEK162;   Drug: vemurafenib
    Sponsors:   Novartis;   Novartis Pharmaceuticals
    Recruiting - verified June 2014

  • Conditions:   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: ibrutinib;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Baricitinib;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting - verified July 2014

  • Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: RO5424802;   Drug: RO5424802
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified July 2014

  • Condition:   Psoriatic Arthritis
    Interventions:   Drug: Abatacept;   Drug: Placebo matching with Abatacept
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified July 2014

  • Conditions:   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: lenalidomide;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Condition:   Diabetic Foot Ulcers
    Interventions:   Drug: DSC127;   Drug: placebo vehicle gel;   Drug: Standard of Care gel, Aquasite
    Sponsors:   Derma Sciences, Inc.;   Integrium
    Recruiting - verified July 2014

  • Conditions:   Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
    Intervention:   Drug: Olaparib 300mg tablets
    Sponsors:   AstraZeneca;   Gynecologic Oncology Group (GOG);   Myriad Genetics - BRACAnalysis test for FDA Premarket Approval (PMA)
    Recruiting - verified July 2014

  • Conditions:   Metastatic Gastrointestinal Carcinoid Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Neuroendocrine Carcinoma of the Skin;   Regional Gastrointestinal Carcinoid Tumor;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin;   Thyroid Gland Medullary Carcinoma
    Interventions:   Drug: pazopanib hydrochloride;   Other: placebo;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   High Risk for Cardiovascular Event
    Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Placebo tablet
    Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   The TIMI Study Group;   Hadassah Medical Organization
    Recruiting - verified July 2014

  • Condition:   Bone Pain in Stage I - III Breast Cancer
    Interventions:   Drug: Naproxen;   Drug: Loratadine
    Sponsor:   Amgen
    Recruiting - verified July 2014

  • Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Placebo;   Drug: Adalimumab;   Drug: Baricitinib
    Sponsor:   Eli Lilly and Company
    Recruiting - verified July 2014

  • Conditions:   Rhinitis, Allergic, Perennial;   Rhinitis, Allergic, Nonseasonal
    Interventions:   Biological: MK-8237 tablets;   Biological: Placebo tablets;   Drug: Rescue Medication: Self-Injectable Epinephrine;   Drug: Rescue Medication: Loratadine tablets;   Drug: Rescue Medication: Olopatadine ophthalmic drops;   Drug: Rescue Medication: Mometasone furoate nasal spray
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting - verified July 2014

  • Condition:   Lupus Nephritis
    Interventions:   Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
    Sponsors:   GlaxoSmithKline;   Human Genome Sciences Inc., a GSK Company
    Recruiting - verified July 2014

  • Condition:   Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
    Intervention:   Biological: Darbepoetin alfa
    Sponsor:   Amgen
    Recruiting - verified July 2014

  • Conditions:   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
    Interventions:   Biological: bevacizumab;   Biological: trebananib;   Other: placebo;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: BKM120 Matching placebo;   Drug: Fulvestrant;   Drug: BKM120
    Sponsors:   Novartis;   Novartis Pharmaceuticals
    Recruiting - verified June 2014

  • Condition:   Cardiovascular Disease
    Interventions:   Drug: Methotrexate;   Drug: Placebo
    Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified July 2013

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Drug: pazopanib hydrochloride;   Other: placebo;   Other: quality-of-life assessment;   Other: questionnaire administration;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Condition:   Asthma
    Interventions:   Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg;   Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg;   Drug: Mometasone Furoate MDI 100 mcg;   Drug: Mometasone Furoate MDI 200 mcg;   Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI;   Drug: Prednisone/prednisolone
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Interventions:   Biological: Elotuzumab;   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone
    Sponsors:   Bristol-Myers Squibb;   AbbVie
    Recruiting - verified October 2013

  • Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Sexuality and Reproductive Issues;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
    Interventions:   Drug: cisplatin;   Drug: paclitaxel;   Drug: carboplatin;   Radiation: external beam radiation therapy;   Radiation: brachytherapy;   Procedure: quality-of-life assessment
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Cognitive/Functional Effects;   Neurotoxicity;   Pain;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Therapy-related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: clofarabine;   Drug: doxorubicin hydrochloride;   Drug: hydrocortisone sodium succinate;   Radiation: selective external radiation therapy;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: cyclophosphamide;   Drug: mercaptopurine tablet;   Drug: leucovorin calcium;   Drug: thioguanine;   Drug: etoposide
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Proteinuria;   Idiopathic Membranous Nephropathy
    Interventions:   Drug: Repository Corticotropin Injection;   Drug: Placebo
    Sponsor:   Questcor Pharmaceuticals, Inc.
    Recruiting - verified June 2014

  • Conditions:   Adult Acute Erythroid Leukemia (M6);   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
    Interventions:   Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: mitoxantrone hydrochloride;   Drug: sorafenib tosylate;   Drug: cytarabine;   Drug: etoposide;   Drug: bortezomib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608; HuLuc63);   Biological: Elotuzumab (BMS-901608; HuLuc63)
    Sponsors:   Bristol-Myers Squibb;   AbbVie
    Recruiting - verified January 2014

  • Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Fungal Infection;   Neutropenia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
    Interventions:   Drug: caspofungin acetate;   Drug: fluconazole;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Recurrent Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
    Interventions:   Biological: ipilimumab;   Biological: recombinant interferon alfa-2b;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Light Chain Deposition Disease;   Smoldering Multiple Myeloma
    Interventions:   Drug: lenalidomide;   Other: clinical observation;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Cardiovascular Disease
    Interventions:   Drug: Febuxostat;   Drug: Allopurinol
    Sponsors:   Takeda;   Teijin
    Recruiting - verified June 2014

  • Conditions:   Distal Urethral Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Proximal Urethral Cancer;   Recurrent Bladder Cancer;   Recurrent Prostate Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Stage IV Bladder Cancer;   Stage IV Prostate Cancer;   Transitional Cell Carcinoma of the Bladder;   Urethral Cancer Associated With Invasive Bladder Cancer
    Interventions:   Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Other: placebo;   Biological: bevacizumab;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Non-Small Cell Lung Cancer;   Anemia;   Cancer;   Lung Cancer
    Interventions:   Drug: darbepoetin alfa 500 mcg Q3W;   Drug: placebo
    Sponsor:   Amgen
    Recruiting - verified July 2014

  • Conditions:   Deep Vein Thrombosis;   Venous Thrombosis;   Postphlebitic Syndrome;   Venous Thromboembolism;   Post Thrombotic Syndrome
    Intervention:   Drug: Recombinant tissue plasminogen activator (rt-PA)
    Sponsors:   Washington University School of Medicine;   McMaster University;   Ontario Clinical Oncology Group (OCOG);   National Heart, Lung, and Blood Institute (NHLBI);   BSN Medical Inc;   Genentech;   Covidien;   Bayer;   Mid America Heart Institute;   Society of Interventional Radiology Foundation;   Massachusetts General Hospital
    Recruiting - verified July 2014

  • Condition:   Ductal Breast Carcinoma in Situ
    Interventions:   Biological: trastuzumab;   Radiation: whole breast irradiation;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
    Interventions:   Drug: docetaxel;   Drug: cisplatin;   Drug: carboplatin;   Drug: fluorouracil;   Biological: bevacizumab;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
    Interventions:   Drug: paclitaxel;   Drug: docetaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Condition:   Arthritis, Rheumatoid
    Interventions:   Drug: CP-690,550;   Drug: CP-690,550
    Sponsor:   Pfizer
    Recruiting - verified June 2014

  • Conditions:   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: daunorubicin hydrochloride;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: mercaptopurine;   Radiation: radiation therapy;   Drug: nelarabine;   Drug: doxorubicin hydrochloride;   Drug: asparaginase;   Drug: dexamethasone;   Drug: thioguanine;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Arthritis, Rheumatoid
    Interventions:   Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
    Sponsors:   Pfizer;   The Cleveland Clinic
    Recruiting - verified July 2014

  • Conditions:   Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Drug: isotretinoin;   Biological: sargramostim;   Biological: dinutuximab;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Sarcoma
    Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   University of Leicester;   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organisation for Research and Treatment of Cancer - EORTC;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
    Recruiting - verified June 2012